PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|August 2, 2015
- Pharmaceutical Technology-08-02-2015
- Volume 39
- Issue 8
Mass Spectrometer Improves Efficiency
Shimadzu’s LCMS-8060 triple quadrupole mass spectrometer is designed for LC/MS/MS quantitation of highly sensitive applications.
Shimadzu’s LCMS-8060 triple quadrupole mass spectrometer is designed for LC/MS/MS quantitation of highly sensitive applications and can detect substances at ultra-trace levels as they occur in complex matrices or in small sample concentrations that must be diluted to avoid matrix effects. The newly developed UF-Qarray ion guide increases sensitivity by enhancing ion signal intensity and reducing noise. In addition, the LCMS-8060 has an increased data-acquisition scan speed of 30,000 u/sec and a polarity switching time of 5 msec. The faster polarity switching time maximizes dwell times and helps to optimize cycle time.
Shimadzu
Articles in this issue
about 11 years ago
Getting Comfortable With Leanabout 11 years ago
Black Specks in Tablet Stability Samplesabout 11 years ago
Environmental Containment Performance—Is There Accountability?about 11 years ago
Implementing Electronic Production Recordsabout 11 years ago
Understanding Risks in Pharmaceutical Shippingabout 11 years ago
Outsourcing Becoming More Cost Competitiveabout 11 years ago
Regulation of Medical Devices and Companion Diagnosticsabout 11 years ago
Campaign Against Fake Drugs Gains Momentumabout 11 years ago
Defining Crucial CAPA Componentsabout 11 years ago
Taking the Pulse of Manufacturing Trends and Equipment UseRelated to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.